Weizmann researchers contributed to two multiple sclerosis medicines through separate lines of work. Ruth Arnon, Michael Sela, and Dvora Teitelbaum developed copolymer-1, later called glatiramer acetate and marketed as Copaxone. Michel Revel’s interferon research helped enable recombinant interferon beta-1a, marketed as Rebif.
Copolymer-1 became Copaxone
In 1968, Arnon, Sela, and Teitelbaum synthesized molecules resembling part of myelin, the protective coating around nerve fibers. They intended to create an experimental model for studying MS. Copolymer-1 instead suppressed experimental autoimmune encephalomyelitis in animals, prompting further study of its therapeutic potential. The Institute’s Copaxone chronology documents the research and development sequence.
Teva conducted clinical development and submitted the drug file to the U.S. Food and Drug Administration on June 14, 1995. The FDA approved Copaxone for MS on December 23, 1996. The later Weizmann account of Arnon’s work describes the long path from laboratory research to clinical trials and approval. Copaxone’s active ingredient is glatiramer acetate.
Rebif came from interferon research
Rebif contains recombinant interferon beta-1a, not glatiramer acetate. Revel and colleagues studied interferon and helped establish a route for producing human interferon in recombinant form. Weizmann’s profile of Revel explains that interferon acts through a different immune mechanism from Copaxone and traces the product’s manufacturing history, including production at InterPharm in Israel before it moved to Switzerland in 2005.
These examples show distinct routes from science to treatment: the Copaxone story began with a synthetic molecule and an unexpected result in an animal model, while Rebif followed interferon biology and recombinant production. Research teams made foundational contributions; clinical trials, manufacturers, and regulators also shaped the medicines that patients received.